Let the Guard Down: cAMP Activators Can Improve Immunotherapy in GBM

Cancer Immunol Res. 2023 Sep 12:OF1-OF2. doi: 10.1158/2326-6066.CIR-23-0667. Online ahead of print.ABSTRACTEnhancing T-cell infiltration into glioblastoma (GBM) tumors has proven challenging yet remains crucial for improving the efficacy of immunotherapy for patients with this deadly cancer. In this issue, Qin, Huang, Li, and colleagues find that inhibiting vasculature formation driven by cancer stem cells is a promising target to enhance immunotherapy in GBM. See related article by Qin et al. (2).PMID:37702792 | DOI:10.1158/2326-6066.CIR-23-0667
Source: Cell Research - Category: Cytology Authors: Source Type: research